Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions
Alimentary Pharmacology & Therapeutics · 2026-05 · 63 (10) · 1423-1424
DOI: 10.1111/apt.70551 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, published online on 2026-03-07. Written by Mohammad Saeid Rezaee-Zavareh and 1 co-authors. Institution: Middle East Liver Diseases (MELD) Center, Tehran, Iran. Cited 1 times so far (Crossref); 10 references. Funded by: NCI NIH HHS, National Cancer Institute.
Abstract (original language)
Není k dispozici žádný abstrakt.
Authors and institutions
- Middle East Liver Diseases (MELD) Center, Tehran, Iran.
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
- Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
ORCID profiles: Ju Dong Yang
Funding
- NCI NIH HHS
- National Cancer Institute
Cite
APA
Rezaee-Zavareh, M. S., & Yang, J. D. (2026). Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Alimentary Pharmacology & Therapeutics, 63(10), 1423-1424. https://doi.org/10.1111/apt.70551
Vancouver
Rezaee-Zavareh MS, Yang JD. Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions. Alimentary Pharmacology & Therapeutics. 2026;63(10):1423-1424. doi:10.1111/apt.70551
BibTeX
@article{RezaeeZavareh2026,
author = {Rezaee-Zavareh, Mohammad Saeid and Yang, Ju Dong},
title = {Editorial: Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Prior to Liver Transplantation—Current Evidence and Future Directions},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {10},
pages = {1423--1424},
doi = {10.1111/apt.70551}
}
EUVIMED